Company profile: ImmuPharma
1.1 - Company Overview
Company description
- Provider of drug discovery and development focused on pioneering, novel therapies in specialist therapeutic areas with few existing treatments. Pipeline includes P140 (Lupuzor) in Phase 3 for SLE, P140 in Phase 2/3 for CIDP, BioAMB (amphotericin-B variant) in preclinical for serious fungal infections, and BioCIN (vancomycin-based) in preclinical for severe bacterial infections.
Products and services
- P140 (Lupuzor™) for SLE: Engineers a Phase 3 clinical-stage therapy that aims to restore immune system function without immunosuppression, for treating systemic lupus erythematosus
- BioAMB: Constructs a preclinical amphotericin-B variant designed to reduce toxicity and improve tolerance for treating serious fungal infections in vulnerable patients
- P140 for CIDP: Develops a Phase 2/3 clinical-stage treatment to reduce Chronic Inflammatory Demyelinating Polyneuropathy flares and lessen hospital intravenous therapy requirements
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ImmuPharma
Alpine Immune Sciences
HQ: United States
Website
- Description: Provider of protein-based immunotherapies for autoimmune and inflammatory diseases, using a proprietary directed evolution platform to engineer native immune proteins into multi-targeted therapeutics. Pipeline includes povetacicept (ALPN-303), a dual BAFF/APRIL antagonist, and acazicolcept (ALPN-101), a dual CD28/ICOS antagonist; conducts clinical trials on investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpine Immune Sciences company profile →
Grifols
HQ: Spain
Website
- Description: Provider of healthcare solutions operating in Bioscience, Hospital, and Diagnostic segments. The Bioscience segment engages in the research, development, production, and commercialization of plasma derivates. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing diagnostics products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grifols company profile →
PvP Biologics
HQ: United States
Website
- Description: Provider of a therapeutic oral enzyme for celiac disease, developing KumaMax to break down the immuno-reactive parts of gluten in the stomach to help reduce symptoms and intestinal damage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PvP Biologics company profile →
Step Pharma
HQ: France
Website
- Description: Provider of CTPS1 inhibition therapies, developing STP938, an orally bioavailable CTPS1 inhibitor in clinical development for treating blood cancers and potentially solid tumors. The approach targets the CTPS1 enzyme to inhibit a key step in nucleotide synthesis to treat various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Step Pharma company profile →
ADMA Biologics
HQ: United States
Website
- Description: Provider of plasma-based biologics, including ASCENIV IVIG for primary immunodeficiency disease (PIDD) and other immune-compromised conditions; BIVIGAM IVIG for primary humoral immunodeficiency (PI); Nabi-HB hyperimmune globulin to prevent hepatitis B infection following exposure; and ADMA BioCenters, a network of plasma collection centers supplying high-quality plasma for immunoglobulin manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADMA Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ImmuPharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ImmuPharma
2.2 - Growth funds investing in similar companies to ImmuPharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ImmuPharma
4.2 - Public trading comparable groups for ImmuPharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →